feed,title,long_url,short_url
Benzinga,Regulus Therapeutics Presents Additional Data From Rare Kidney Disease Program,https://benzinga.com/general/biotech/21/06/21723808/regulus-therapeutics-presents-additional-data-from-rare-kidney-disease-program,https://j.mp/3dh92VN
Benzinga,Alzheimer's Biotech Acumen Pharmaceuticals Prices $125M IPO Soon After Biogen's Aduhelm Approval,https://benzinga.com/general/biotech/21/06/21725301/alzheimers-biotech-acumen-pharmaceuticals-prices-125m-ipo-soon-after-biogens-aduhelm-approval,https://j.mp/2Sq1oBe
